Guru P. Sonpavde, GU Oncology Director at Advent Health Cancer Institute, shared on X:
“Pleased to review emerging vaccine immunotherapy approaches to treat bladder cancer, urothelial carcinoma.
We discuss:
1) peptide,
2) cellular and
3) nucleic acid (DNA, RNA) approaches
Several challenges remain:
1) heterogeneity of cancer cells,
2) Immunogenicity of antigens/neoantigens,
3) downregulation of antigen presentation,
4) Inhibitory immune microenvironment,
5) cost and efficiency of manufacturing processes to have a global impact”
Vaccine approaches to treat urothelial cancer
Autors: Giulia Claire Giudice and Guru P. Sonpavde.
Source: Guru P. Sonpavde/X